BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Rockland Immunochemicals Releases Host Cell Protein Antibodies


1/29/2013 11:10:13 AM

BOYERTOWN, PA. January 29, 2013 – Rockland Immunochemicals, Inc., a biotechnology company focusing on antibodies and antibody-based tools for basic research, assay development, and preclinical studies, today announced the release of Host Cell Protein (HCP) antibodies that detect high, medium and low molecular weight proteins. Host Cell Proteins are process-related impurities derived from a host cell expression system that may be present in trace amounts in a final drug substance. HCP antibodies are used to detect impurities in biologically-based therapeutics. Assays are further developed using custom-manufactured process specific antibodies.

Rockland’s new HCP antibodies will be released and a standardized HCP immunoassay development process presented during the Well Characterized Biotechnology Pharmaceuticals (WCBP) Symposium in Washington, DC January 29-31. This United States Food and Drug Administration (FDA) co-sponsored symposium is the pre-eminent conference addressing the analytical development/regulatory control interface for biotechnology derived health intervention products. The FDA requires that pharmaceutical and biotechnology companies producing therapeutic antibodies minimize HCP contamination to an acceptable level. Failure to identify and sufficiently remove contaminants early in drug development can result in reduced drug efficacy or adverse toxic or immunological reactions in patients.

ELISA, the most widely used assay for determining the presence of HCPs, uses a polyclonal antibody mixture raised against host cell proteins. The accepted workflow for evaluating the immunocoverage of HCP antibodies involves 2-D gel electrophoresis followed by Western blotting. Rockland now provides Bioprocessing researchers with antibodies and custom HCP assay development services that streamlines and regulates this workflow.

At the WCBP Symposium, Rockland researchers will present data that shows an improved standardized immunoassay development process for HCP detection using 2D electrophoresis and western blotting. In collaboration with Bio-Rad, the PROTEAN® i12™ IEF System was used to develop the HCP antibodies and measure/calibrate assays. Detecting impurities often unseen by 1-D electrophoresis, this system delivers more complete insight into the immunocoverage of protein components of the host cell lysate. The newly developed Rockland antibodies have been fully evaluated using the 2-D electrophoresis workflow and provide efficient immunocoverage of E.coli HCP.

“Rockland’s expertise in HCP antibodies and HCP assay development services has allowed Bio-Rad to affirm the value of optimized IEF separations in generating a robust 2D-electrophoresis based assay for evaluating anti-HCP antibodies, ” said Sricharan Bandhakavi, Senior Scientist at Bio-Rad Laboratories.

"Over the last decade, BioPharma has invested significant amounts of money to develop large molecule (antibody) drugs. As these drugs move forward in the approval process, reagents and assays used to analyze purity will increase in importance,” commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “With our well-developed antibody and assay technology, Rockland is well positioned to take advantage of this opportunity and set the standard for optimal quality of application."

For more information on Rockland’s HCP antibodies and assays, please visit http://www.rockland-inc.com/hcp.aspx. About Rockland Immunochemicals

Rockland Immunochemicals has supported the biopharma and diagnostic industries with antibodies and antibody based tools™ for basic research, assay development and preclinical studies for 50 years. With facilities in Pennsylvania, Rockland manufactures over 10,000 products ideally suited for integration into various assays performed on different platforms including western blot, immunohistochemistry (IHC), immunofluorescence (IF), microscopy, ELISA and FLOW cytometry. Additional information about Rockland’s products and services can be found on the company’s web site at www.rockland-inc.com.

For additional information regarding this announcement, please contact:

Tabitha Bauman

Communications, Rockland Immunochemicals, Inc.

Phone: 610.369.1008

Email: tabitha.bauman@rockland-inc.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->